IMPL News

12 IPOs raised $3.7 billion this past week, led by software maker UiPath (PATH), which raised more than $1 billion in its public debut. The pipeline remained active, with 11 IPOs and one direct listing submitting initial filings. SPAC activity continued to decline, with no pricings for the first week ever in 2021 and just four new filings. The largest deal...read more

Impel NeuroPharma, a late-stage developer of intranasal drug formulations for migraines and CNS diseases, raised $80 million by offering 5.3 million shares at $15, the midpoint of the range of $14 to $16. At pricing, the company commands a fully diluted market value of $315 million. The company indicated in its filing that existing shareholders intended to purchase a "substantial...read more

Impel NeuroPharma, a late stage biotech developing formulations of drugs for CNS diseases, announced terms for its IPO on Monday. The Seattle, WA-based company plans to raise $80 million by offering 5.3 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Impel NeuroPharma would command a fully diluted market value of $316 million. Impel's...read more

Updated Monday, 4/19. 11 IPOs are scheduled to raise a total of $3.6 billion in the week ahead, led by software maker UiPath (PATH). The largest IPO of the week, UiPath (PATH) plans to raise $990 million at a $26.0 billion market cap. The company provides software that identifies automation opportunities across organizations....read more